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CObjectives: To estimate the total financial burden of chronic hepatitis
B virus (HBV) infection for Vietnam by quantifying the direct medical,
the direct nonmedical, and indirect costs among patients with various
stages of chronic HBV infection. Methods: Direct medical cost data
were retrieved retrospectively frommedical histories of inpatients and
outpatients in 2008 from a large referral hospital in Hanoi, Vietnam.
Direct nonmedical and indirect costs data were obtained from face-to-
face interviews of outpatients from the same hospital. The treatment
cost per patient per chronic HBV infection stage was multiplied by the
total estimated patients inVietnam to get the total cost of illness for the
nation. Results: Nationally, the total cost attributable to chronic HBV
infection and its complications in 2008 was estimated to be approxi-
mately US $4.4 billion, with the direct medical cost accounting for
about 70% of that estimate. The cost of antivirals was the major cost
driver in treating chronic HBV infection. The per-patient total annual
direct medical cost increased with the severity of the disease, with the O
hav
y and
al So
doi:10.1016/j.vhri.2012.03.008stimated costs for chronic HBV infection and hepatocellular carci-
oma as US $450.35 and US $1883.05, respectively. When compared
ith the 2008 per-capita gross domestic product of US $1024, the
nancial burden of treating chronic HBV infection is very high in
ietnam. Conclusions: This study confirmed that chronic HBV infec-
ion poses a significant financial burden for the average patient and
hat lacking treatment would become a social issue in Vietnam. Al-
hough HBV vaccination has been universally implemented, more
ealth care investment and the greater availability of affordable med-
cations are still needed to attain equity in proper treatment for pa-
ients with HBV infection.
eywords: chronic hepatitis B, cost of illness, direct medical cost, indi-
ect cost.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hepatitis B virus (HBV) is one of the most prevalent blood-borne
viruses worldwide, with chronic HBV infection afflicting more
than 350 million people [1]. Major clinical consequences of HBV
infection include liver failure, cirrhosis, and hepatocellular car-
cinoma (HCC) [2,3]. These complications lead to more than 1
illion deaths each year [3–5]. Thus, HBV infection is an
important public health problem, especially for developing
countries where the endemicity is often either intermediate or
high.
Vietnam is a high-endemic country for HBV infection [6]. Pop-
ulation surveys from the two biggest cities, Hanoi andHoChiMinh
City, have shown a positive hepatitis B surface antigen (HBsAg)
rate of 9% to14% [7,8]. High HBsAg prevalence in Vietnam is sup-
ported by another small survey of children in rural regions. In this
survey, the HBsAg rate was 19.5% [9]. While very little data exist
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Published by Elsevier Inc.in Vietnam on the proportion of patients who were HBsAg and
have chronic HBV infection, cirrhosis, or HCC, the international
literature has reported that 75% to 80% of patients with chronic
HBV infection, 34% of patients with cirrhosis, and 72% of patients
with HCC were also HBsAg [10]. Hence, chronic HBV infection
and the resulting liver diseases would pose a heavy burden for the
Vietnamese health care system.
At the per-capita gross domestic product of US $1024 [11], the
cost of treatment for diseases stemming from HBV infection is
significant for the average Vietnamese patient. Moreover, anti-
viral drugs remain expensive. Comprehensive analyses of the
financial burden of HBV infection in Vietnam, however, are very
limited. In view of this, we conducted a cost-of-illness study of
HBV infection by using data from one major referral hospital in
Vietnam and extrapolated the results nationally. Our analyses
should provide the Vietnamese decision makers some guidance
on resource allocation for health, particularly for HBV-related
conditions.
e no conflicts of interest with regard to the content of this
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The study contains two parts: 1) quantification of the direct med-
ical cost and 2) quantification of the direct nonmedical cost and
the indirect cost of HBV infection. The financial burden to the
Vietnamese society is represented by the total cost (directmedical,
direct nonmedical, and indirect costs) multiplied by the estimated
number of infected subjects in Vietnam. The study protocol was
approved by the Director of BachMai Hospital in Hanoi, where the
study was carried out. Bach Mai Hospital, a 1400-bed hospital, is
among the largest hospitals in Vietnam. It is a highly specialized
multidisciplinary medical facility with a focus on internal medi-
cine and the most active in treating hepatitis B patients in Hanoi.
In the cost analysis, the study followed the bottom-up approach
[12]. Direct medical costs were estimated from retrospective anal-
ysis. Direct nonmedical and indirect costs were obtained from pa-
tient interviews.
Part 1: Measurement of direct medical cost
Data were collected from medical and financial records of Bach
Mai Hospital from January 1 to December 31, 2008. The records for
all inpatients treated at the Department of Infectious Diseases and
all outpatients treated at the Infectious Diseases Unit of the Out-
patient Department were included.
By using the codes established by the International Statistical
Classification of Diseases, 10th Revision, we identified and retrieved
information on HBV patients classified under B18 (chronic HBV
infection patients), K74 (compensated cirrhosis [CC] and decom-
pensated cirrhosis [DC]), and C22 (HCC). Patients coded with K74
were subsequently differentiated as either CC or DC through clin-
ical diagnosis from patient case notes.
Cost consideration
The total direct medical cost related to the treatment of chronic
HBV infection and associated complications included clinic visit
cost (outpatient visits and hospitalizations), investigation cost
(laboratory tests and procedures), and drug costs (antiviral drugs
and other medicines) and other services (bed costs, meals, etc.).
The study assessed resource utilization based on hospital
charges in 2008 and was expressed in US $ (US $1  VND17,803)
[13]. Because Bach Mai Hospital is a public nonprofit health care
institution with most service charges based on cost recovery, the
use of charge for the estimation of costs would be themost appro-
priate approach [14].
Calculation of direct medical cost
The total annual direct medical cost per patient from each cate-
gory of chronic HBV infection was calculated by the following for-
mulae:
Annual cost ⁄ patientCost ⁄ visitVisits ⁄ yearCost ⁄ admission
Admissions ⁄ year
where visits/year  aggregated visits of observed patient cases/
aggregated observed patient cases, and admissions/year  aggre-
gated admissions of observed patient cases/aggregated observed
patient cases.
Part 2: Measurement of direct nonmedical and indirect costs
Estimations of direct nonmedical (expenses on travel, accommo-
dation, and meals) and indirect costs (medical leave, time off, and
productivity loss) were collected through interviews of outpa-
tients after informed consents were obtained. In the cases where
no consenting subject for a particular category of clinical diagnosis(described above) was available, physicians were interviewed as
surrogates for their opinions on the likely costs to the patient.
For the working group, medical leave and time off were the
components for the indirect cost. The annual cost of day offs for
medical leave was calculated by multiplying the days taken for
medical leave by the average daily-wage rate. The annual time-off
cost for outpatient visits was calculated by multiplying the total
time off by the average hourly earnings. For daily and hourly wage
calculation, a 5-day workweek and an 8-hour workday were as-
sumed.
For the nonworking group, productivity loss was used as the
indicator of indirect cost and was calculated by assuming that the
minimum wage was the monthly wage [15].
Estimation of prevalence
To estimate numbers of HBV carriers and cirrhosis cases, data
were extrapolated from the study on HBV infections and HBV-
related cirrhosis in Vietnam in 2005, which were estimated at
10.05% and 481 per 100,000, respectively [16]. Assuming the same
prevalence rate as in 2005 and extrapolating to the 2008 popula-
tion of 86,084,547 in Vietnam [17], the estimated HBV carriers and
patients with cirrhosis were 8,651,497 and 414,067, respectively.
No official data on the ratio of CC to DC cases were available in
Vietnam. By using the ratio of CC toDC (8:1) at BachMaiHospital as
a guide, it would translate to approximately 368,059 CC and 46,007
DC cases.
The prevalence of HCC was calculated by multiplying the HCC
incidence rate (estimated at 0.019% in 2005 [16]) with the average
duration of HCC (estimation of 1 year [18–20]); HCC cases in Viet-
nam in 2008 were 16,356.
Subtracting the cirrhosis andHCC cases from total chronicHBV
carriers, the number of chronic HBV infection caseswas estimated
to be 8,221,074.
Sensitivity analysis
For the directmedical cost, two one-way sensitivity analyses were
performed. In the first sensitivity analysis, the lower and upper
limits of the direct medical cost (95% confidence interval) were
tested. In the second sensitivity analysis, the number of patients
in different chronic HBV disease stages was varied as follows:
1. Using the prevalence rate of HBV-infected patients of 8% to 16%
[7–9,21] as the lower and upper limits, respectively, for estimat-
ing the number of chronic HBV carriers;
2. Using survival times from 5months to 16months [22–24] as the
lower and upper limits, respectively, for estimating the preva-
lence of HCC subjects; and
. Applying the base-case ratio (4.79%) between cirrhosis cases
and chronic HBV carriers [16] to the lower and upper limits of
chronic HBV carriers to estimate the lower and upper limits for
liver cirrhosis cases.
For direct nonmedical and indirect costs, two one-way sensi-
ivity analyses were also performed. In the first analysis, the 25th
nd 75th percentiles of the indirect cost were tested. In the second
nalysis, the number of patients in each disease stage was varied
s for the direct medical cost.
Two-way sensitivity analyses (best- and worst-case scenarios)
ere conducted to test the combined effects of varying both the
umber of subjects and the treatment costs.
Results
Direct medical cost
A total of 904 patient cases (470 outpatients and 434 inpatients)
were included for analysis, consisting of 226 chronic HBV infec-
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inpatient cases and the outpatient cases was 46.4 years (range
13–83 years) and 39.4 years (range 15–61 years), respectively.
The results show that the annual direct medical cost of the
treatment increased with disease progression, with drug costs ac-
counting for the largest part of the direct medical cost. Details on
annual health care utilization and the estimated average annual
treatment cost per patient for each disease stage are listed in Ta-
bles 1 and 2, respectively.
Lamivudine was the most frequently used antiviral agent in
our study, likely because it is currently the only agent reimbursed
by the health insurance of Vietnam.
In 2008, the total estimated direct medical cost associated with
different chronic HBV infection stageswas US $4 billion (Table 3A).
Results of the first and second one-way sensitivity analyses
were between US $2.8 and 5.5 billion and between US $3.2 and 6.4
billion, respectively (Table 3B). The two-way sensitivity analyses,
however, resulted in a range of US $2.2 to 8.8 billion (Table 3B).
Direct nonmedical and indirect costs
Fifty-one patients with chronic HBV infection (mean age 36.12
[range 16–59 years] years) participated in the study.
Because the cost distribution was skewed, the median values
were used to calculate indirect costs. Details on direct nonmedical
and indirect costs are shown in Table 4. The base-case estimation
or total direct nonmedical and indirect costs for all HBV disease
tages in Vietnamwas roughly US $375 million (Table 5A). Results
f one-way sensitivity and two-way sensitivity analyses for esti-
Table 1 – Annual outpatient visits and hospitalizations for
Vietnam in 2008*.
Chronic hepatitis B Compensated c
Outpatient visits
Per person per year 3.84 (3.02–4.66) 4.31 (2.65–5.
No. of hospitalizations
Per person per year 0.17 (0.12–0.22) 0.27 (0.21–0.
Length of stay
Per admission (d) 2.35 (2.11–2.59) 2.50 (2.02–2.
HBV, hepatitis B virus.
* Liver transplant program was not established at Bach Mai Hospital
Table 2 – Average annual direct medical cost (in US $) per p
compositions in Vietnam in 2008.
Chronic hepatitis
B
Co
Total cost (US $) 450.35 (319.73–599.66) 690.43
Outpatient cost 439.85 (313.87–582.88) 658.18
Inpatient cost 10.49 (5.87–16.78) 32.25
Cost composition (%)
Antiviral drugs* 14.85
Other medications* 54.28
Examination/laboratory tests,
procedures,† other
services‡
29.22
Consultations 1.65
Total 100.00
HBV, hepatitis B virus.
* Cost of medications  (Medication pricei  amounti).
† Cost of examinations and laboratory tests  (Unit costi  Utilizat
‡ Other services include bed cost and meals.mating direct nonmedical and indirect costs are summarized in
Table 5B.
Cost of illness for chronic HBV infection estimation
Table 6 shows that the cost of illness for chronic HBV infection in
Vietnam in 2008 was estimated at US $4.4 billion, with chronic
HBV infection as the most costly component.
Discussion
To the best of our knowledge, this is the first cost-of-illness study
for chronic HBV infections in Vietnam. Our results clearly showed
that chronic HBV infection and its complications impose a signif-
icant financial burden on the Vietnamese society and health care
system. If all patients with chronic HBV infection and its various
disease stages were treated in hospitals, the total annual cost
would amount to US $4.4 billion, which is 5% of the gross do-
mestic product of Vietnam in 2008.
In reality, the Vietnamese government’s expenditure on health
accounted for only a quarter of the total national health expendi-
ture with the remainder coming from patients’ out-of-pocket pay-
ment [25,26]. At the current per-capita gross domestic product of
US $1024 [11], the treatment costs of chronic HBV infectionswould
be a significant financial burden for the average Vietnamese pa-
tient. This might imply that a substantial number of patients with
HBV infections who cannot bear these costs may be undertreated
or untreated.
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ditional medicines as an alternative. From interviews with physi-
cians from Bach Mai Hospital, it appeared that only 1% of patients
with chronic HBV infection and other complications received hos-
pital treatment.
In our study, resource utilization pattern for the direct medical
costs was consistent with other published studies, with direct
medical costs increasing with disease progression [27–29]. Ex-
penses on medications were the largest cost driver for the direct
treatment cost for chronic HBV infection, CC, and DD, accounting
for more than 70% of the total direct medical cost. This might be
explained by the high drug prices in Vietnam.
Indeed, the prices of nucleosides are still very costly inVietnam
and antiviral therapy is affordable for only a small proportion of
HBV-infected patients. This problem is exacerbated by the higher
drug prices in public pharmacies [30], where many patients with
Table 3 – (A) Base-case estimates and (B) sensitivity analys
disease stages in Vietnam in 2008.
A. Base-case estimates
Disease
category
Number of
patients
CHB 8,221,074.00
CC 368,059.00
DC 46,007.00
HCC 16,356.00
Total 8,651,497.00
B. Sensitivity analysis
Disease
category
Range of estimated
number of patients
Range of estimated
direct medical cost
CHB 6,533,015–13,058,282 319.73–599.66
CC 308,322–616,644 376.05–1,234.37
DC 38,540–77,080 642.45–1,723.78
HCC 6,887–21,521 1,228.03–3,870.65
Total 6,886,764–13,773,528 2,566.26–7,428.47
Disease
category
Range of estimated
number of patients
Range of estimated
direct medical cost
CHB 6,533,015–13,058,282 319.73–599.66
CC 308,322–616,644 376.05–1,234.37
DC 38,540–77,080 642.45–1,723.78
HCC 6,887–21,521 1,228.03–3,870.65
Total 6,886,764–13,773,528 2,566.26–7,428.47
CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompens
Table 4 – Annual direct nonmedical and indirect costs (US
Vietnam in 2008.
Disease
category
Medical leave
and time off
Productivity
loss*
CHB 1.04 15.32
CC 1.73 25.53
DC 17.63 71.49
HCC 76.19 80.27
Total 96.59 192.61
CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompens
* Monthly cost of reduced productivity  Reported loss of productivisick days due to HBV/total number working days of a month.chronic HBV infections would purchase their medications. It was
estimated that for chronic diseases, 1-month treatment cost
might be equivalent to 22-day minimum wages for generic drug
and up to 50-day wages for an innovator brand [30]. Thus, if more
generic drugs could either be manufactured domestically at a
lower cost or imported at a lower price, the affordability of chronic
HBV infection treatment would increase.
Because many patients with chronic HBV infection reside out-
side of Hanoi, direct nonmedical and indirect cost appeared to be
a substantial part of cost in Vietnam.
Our study also has several limitations. First is the issue of rep-
resentativeness of the patient sample. Ideally, inpatients after dis-
charge would have to return for follow-up assessment and ther-
apy. This does not, however, happen in Vietnam. Many patients
with chronic HBV infections live in provinces distant from Hanoi
and are agricultural workers with very low income, thusmaking it
f total direct medical cost of chronic HBV infection by
an direct medical
per patient (US $)
Total direct medical
cost per year (US $)
450.35 3,702,344,156.83
690.43 254,118,890.27
1,114.50 51,274,910.42
1,883.05 30,799,174.35
4,138.33 4,038,537,131.88
First one-way sensitivity
analysis (US $)
Second one-way sensitivity
analysis (US $)
2,628,542,811–4,929,838,419 2,942,130,126–5,880,771,131
138,409,271–454,322,691 212,874,616–425,749,232
29,557,257–79,306,656 42,953,185–85,906,371
20,085,706–63,308,668 12,968,124–40,525,388
2,816,595,045–5,526,776,434 3,210,926,051–6,432,952,122
-way sensitivity analysis
st-case scenario) (US $)
Two-way sensitivity analysis
(worst-case scenario) (US $)
2,088,815,738 7,830,512,048
115,944,939 761,168,906
24,760,006 132,869,790
8,457,139 83,300,879
2,237,977,823 8,807,851,623
cirrhosis; HCC, hepatocellular carcinoma.
chronic HBV infection by disease stages per patient in
ransportation, meals,
accommodation
Annual direct nonmedical
and indirect costs
22.62 38.98
148.85 176.11
154.11 243.23
153.12 309.58
478.70 767.90
cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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Hence, our outpatient samples were from those who attended the
outpatient clinic and may not be truly representative as evident
that formal care was not required by any of the participants.
In addition, we collected data only from one central hospital,
albeit the biggest in the north, and not from other two regions of
the country (central and the south). However, as medications ac-
counted for 70% of the total cost in our study and there is little
variation in drug prices across Vietnam, this would allow an ex-
trapolation to the whole country. Likewise, the minimum wage
was applied in estimating medical leave and time off for the indi-
rect cost, and there would not be much deviation of these costs
when our results are extrapolated to different regions in Vietnam.
Extrapolation of treatment cost collected from one hospital to
the national level, however, could be prone to overestimating the
Table 5 – (A) Base-case estimates and (B) sensitivity analys
HBV infection by disease stages in Vietnam in 2008.
A. Base-case estimates
Disease
category
Number of
patients
Mean dire
indirect co
CHB 8,221,074.00
CC 368,059.00
DC 46,007.00
HCC 16,356.00
Total 8,651,497.00
B. Sensitivity analysis
Disease
category
Range of estimated
number of patients
Range of estimated dire
nonmedical and indirect
CHB 6,533,015–13,058,282 15.01–100.15
CC 308,322–616,644 62.30–244.91
DC 38,540–77,080 113.90–250.86
HCC 6,887–21,521 130.25–238.14
Total 6,886,764–13,773,528 321.45–834.05
Disease
category
Range of estimated
number of patients
Range of estimated direct
nonmedical and indirect cos
CHB 6,533,015–13,058,282 15.01–100.15
CC 308,322–616,644 62.30–244.91
DC 38,540–77,080 113.90–250.86
HCC 6,887–21,521 130.25–238.14
Total 6,886,764–13,773,528 321.45–834.05
CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompens
* Lower and upper limits of the cost components (95% confidence inte
of patients was unchanged.
† Cost components remained constant and the number of patients p
Table 6 – Direct medical cost, direct nonmedical and indire
HBV infection in Vietnam in 2008 (US $).
Disease
category
Direct medical
cost
Direct nonmedical and
indirect costs
CHB 3,702,344,157 320,429,256
CC 254,118,890 44,846,050
DC 51,274,910 7,756,533
HCC 30,799,174 2,417,703
Total 4,038,537,132 375,449,542CC, compensated cirrhosis; CHB, chronic hepatitis B; DC, decompensatedtreatment cost of chronic HBV infection in Vietnam. Nonetheless,
in lieu of any cost information in Vietnam, our results could be
viewed as a potential scenario that provides an estimation of what
“might be” the quantum of the cost to fill in an existing informa-
tion gap.
Even with these potential limitations, this first and only cost-of-
illness study on chronicHBV infection inVietnamstill provides valu-
able information for health care decision makers in resource alloca-
tion and planning. Given the high prevalence of HBV infection in
Vietnam, it is imperative that stepsbe takensuchas thecontinuation
of universal HBV vaccination of newborns, a reconsideration of Viet-
namese policies on drug pricing, treatment of chronic HBV infection,
and other initiatives for the prevention of infection.
Source of financial support: Funding for this project was pro-
vided by The Dutch Higher Education Foundation (NUFFIC).
f total direct nonmedical and indirect costs of chronic
onmedical and
r patient (US $)
Total direct nonmedical and
indirect cost per year (US $)
.98 320,429,256
.11 44,846,050
.23 7,756,533
.58 2,417,703
.90 375,449,542
First one-way sensitivity
analysis (US $)*
Second one-way sensitivity
analysis (US $)†
123,363,341–823,309,245 254,634,496–508,967,017
22,931,607–90,141,550 37,567,371–75,134,743
5,240,034–11,541,475 6,497,619–12,995,238
2,130,329–3,894,954 1,017,980–3,181,189
153,665,312–928,887,224 299,717,467–600,278,186
wo-way sensitivity analysis
(best-case scenario) (US $)
Two-way sensitivity analysis
(worst-case scenario) (US $)
98,032,753 1,307,737,174
19,209,723 151,022,492
4,389,558 19,336,503
896,981 5,124,939
122,529,015 1,483,221,108
cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
from the directmedical cost calculationwere tested and the number
sease stage was varied.
sts, and total cost of illness for different stages of chronic
Cost of illness Ratio of direct medical cost to
direct nonmedical and indirect costs
4,022,773,413 11.6:1
298,964,940 5.7:1
59,031,443 6.6:1
33,216,878 12.7:1
4,413,986,674es o
ct n
st pe
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243
309
767
ct
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t
T
ated
rval)ct cocirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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